

CPG Evaluation Form: Pre implementation

Please answer the questions below to help us evaluate the usefulness and effectiveness of our guidelines, as well as learn more about those using the information contained in the publication.

Section A: General Information					
How did you hear about this guideline? Please tick all that apply and provide details where applicable	☐ Event (e.g. DEBRA conference, EB study day) ☐ Recommendation (e.g. family member, clinician)				
Why have you chosen to review this guideline?					
City and country:					
DEBRA group affiliation: If applicable					
Which of the following best describes you? Please tick all that apply	Group A Professionals □ Clinician □ Allied health professional □ Professional carer	Group B Non-professionals Person living with EB *Caregiver (family member) Caregiver (friend) Friend	Group C Other Other (please provide details)		
	Please continue with Section B	Please continue with Section C	Please continue with Section B or C (as appropriate)		
Section B: Professionals					
Your institute: Name and address (including country)					
Tell us about the type of EB services you offer: Please tick all that apply and provide details	□ Hospital □ Commu	nity □ Home service	□ Other (please specify)		

^{*} For the purposes of this document, a caregiver indicates a non-professional. If you are a carer in a professional capacity, please tick the 'Professional carer' option in Group A.



Please tell us who works with EB	☐ Consultant☐ Dermatologis	st		1 1	2 2	3 3	4+ 4+
patients at your	□ Surgeon			1	2	3	4+
institute:	☐ Nurse (specia	alist)		1	2	3	4+
Please tick all that apply and circle the number	☐ Psychologist, psychotherapist			1	2	3	4+
of relevant people	☐ Dietician, nut	tritionist		1	2	3	4+
	□ Dentist			1	2	3	4+
	☐ Physiotherap	pist		1	2	3	4+
	□ Podiatrist			1	2	3	4+
	☐ Occupation	al therapist, hand t	herapist	1	2	3	4+
	☐ Social worker	r/social support	•	1	2	3	4+
	☐ Other (please	* *		1	2	3	4+
		. ,,					
Please give a summary of the EB service(s) your institute provides: 300 words maximum; please attach and use additional pages, if							
needed							
needed	Living with EB (y	years of age)	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply	Living with EB (y		EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide		d neonatal	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply	□ Newborn and	d neonatal ')	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers,	□ Newborn and □ Children (0-7	d neonatal 7) 2)	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers,	□ Newborn and □ Children (0-7 □ Children (8-1	d neonatal 7) 2) 2-18)	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers,	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1	d neonatal 7) 2) 2-18)	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers,	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults	d neonatal 7) 2) 2-18) s (18-25)	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers,	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+)	d neonatal 7) 2) 2-18) s (18-25)	EBS	JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers,	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please	d neonatal 7) 2) 2-18) s (18-25)		JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please	d neonatal 7) 2) 12-18) s (18-25) e specify)		JEB	DDEB	RDEE	s KS
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please	d neonatal 7) 2) 12-18) s (18-25) e specify)		JEB		RDEE	
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do you/your team	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please	d neonatal 7) 2) 12-18) s (18-25) e specify) out this clinical issue	e:				
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do you/your team already know about this clinical	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please Knowledge about	d neonatal 7) 2) 12-18) s (18-25) e specify) out this clinical issue	e:			5	
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do you/your team already know about this clinical issue?	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please Knowledge about	d neonatal 7) 2) 12-18) s (18-25) e specify) out this clinical issue	e:			5	
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do you/your team already know about this clinical issue? Please circle the	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please Knowledge about	d neonatal 7) 2) 12-18) s (18-25) e specify) out this clinical issue	e: 3	4	***	5 Exp	ert
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do you/your team already know about this clinical issue? Please circle the number you feel best reflects your experience	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please Knowledge about 1 None Do you have an	d neonatal 7) 2) 12-18) s (18-25) e specify) out this clinical issue	e: 3 king with yo	4	**	5 Exp Yes	ert No
Target groups: Please tick all that apply and provide approximate numbers, where applicable Before reading the guideline, what information do you/your team already know about this clinical issue? Please circle the number you feel best	□ Newborn and □ Children (0-7 □ Children (8-1 □ Teenagers (1 □ Young adults □ Adults (25+) □ Other (please Knowledge about 1 None Do you have an	d neonatal 7) 2) 12-18) s (18-25) e specify) out this clinical issue 2 n EB specialist work have expertise in t	e: 3 king with yo	4	**	5 Exp Yes	ert No



	How confident are you/your team in providing care for EB patients relating to this issue?				
	1 Not at all confident	2	3	4	5 Extremely confident
	How often do	you/your tea	m manage this	clinical issue?	
	1	2	3	4	5
	Less than yearly	Yearly	Monthly	Weekly	Daily
Describe how you think this guideline will benefit your service users:					
Including patients, clients, families, etc.					
	Se	ection C: Non	-professionals		
Which type of EB do you (your family member/friend) have?			□ DDEB nd) have not of	□ RDEB ficially been di	□ KS agnosed
Before reading the guideline, what	How confiden	t are you to g	et appropriate	care in this clir	nical area?
information do you already know about this clinical issue?	1 Not at all confident	2	3	4	5 Extremely confident
Please circle the number you feel best reflects your experience and/or tick the most appropriate box, where applicable	Why did you indicate this level of confidence? No one is available to help				



ſ		Г						
		How often do you (your family member/friend) experience this problem?						
		1 2 3 4 5						
		Less than yearly	Yearly	Monthly	Weekly	Daily		
		How do you (your family m	ember/friend) n	ormally manag	ge this problem?		
lc	EBRA International (DI Iter for post evaluation If the guideline after its	n measurement	t. The purpose	of this addition				
<u>D</u>	<u>eclaration</u>							
	understand that the in urposes only.	oformation I pro	vide will be u	sed for data col	lection and gui	ideline evaluation		
	understand that all do dentifiable in the evalu		nrough these s	surveys will be a	nonymised and	I will not become		
р	understand that if DI w urposes of being aske een obtained for add	d to complete	the post eval					
a <u>ir</u>	understand I am unde nd that I am able to c ternational.org). I und ontact details provide	change or withous Herstand if cons	draw my cons ent is withdra	ent at any time wn, DI will destro	by notifying DI	(office@debra-		
Ιι	understand I have the	right to ask to	see any inforr	mation and reco	ords held about	t me by DI.		
	I give my cons		ontact me o	after one year	with a post ev	valuation		
Fo	or more details on hov	v DI uses your ir	nformation, pl	ease visit <u>www.c</u>	debra-internatio	onal.org.		
			Contact	Details				
	Full name							
	Signature			Date				
	Email				l			